Tafasitamab for autoimmune blood cell disorders
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA).
- You have not had your spleen removed.
- You have had at least one standard course of rituximab (Rituxan) in the past, with the last dose at least 6 months ago.
- Your disease is currently active and needs treatment (low platelet count for ITP, low hemoglobin for wAIHA).
- You have not had a previous anti-CD19 treatment (like a different antibody or CAR T-cell therapy).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
This trial tests whether adding an anti-CD38 antibody to the standard drug rituximab works better than rituximab alone for adults with long-term immune thrombocytopenia (ITP) who have already tried steroids without lasting success.
This trial tests combining two antibodies (anti-CD38 and rituximab) for adults with chronic ITP who haven't been helped by steroids or other standard treatments. The goal is to see if this drug pair can raise platelet counts and reduce bleeding risk.
This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.
This study tests a new CAR T-cell therapy for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that hasn't improved with standard treatments. The goal is to see if this therapy can eliminate the harmful immune cells causing your condition.
This trial tests a drug called belantamab mafodotin for adults with primary immune thrombocytopenia (ITP) whose platelet levels stayed low after trying steroids and another treatment like TPO-RA or rituximab. The goal is to see if it safely raises platelet counts.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.